FindTrial
Sign In

The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04351347
Enrollment
300
Registered
2020-04-17
Start date
2020-06-16
Completion date
2030-12-01
Last updated
2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

Efficacy of Ivermectin in larger doses in COVID-19 treatment

Detailed description

Clinical Study Evaluating the Efficacy of Ivermectin in higher doses in COVID-19 treatment

Interventions

DRUGIvermectin

ivermectin

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with covid 19

Exclusion criteria

* Allergy or side effects to treatment

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with improvement or died1 monthThe number of patients with improvement or death

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026